Arvinas (ARVN) vs Bright Minds Biosciences (DRUG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Bright Minds Biosciences (DRUG) has outperformed Arvinas (ARVN) over the past year, losing 12.0% versus a loss of 20.3%. Over five years, DRUG leads with a +45.5% price change compared with -91.0% for ARVN. Bright Minds Biosciences is the larger company by market cap ($533.2 million vs $492.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | DRUG |
|---|---|---|
| Share price | $7.64 | $54.05 |
| Market cap | $492.94M | $533.15M |
| 1-day change | +1.73% | +3.94% |
| YTD return | -35.58% | -30.74% |
| 1-year return | -20.33% | -11.99% |
| 5-year return | -91.02% | +45.49% |
| P/E ratio (TTM) | 29.38 | — |
| EPS (TTM) | $0.26 | $-2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.51 | $123.75 |
| 52-week low | $6.97 | $47.23 |
| Distance from 52-week high | -47.35% | -56.32% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +82.33% | +181.17% |
| Average volume | 790.35K | 155.37K |
| Shares outstanding | 64.52M | 9.86M |
| Employees | 246 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
ARVN vs DRUG FAQ
Which is bigger, Arvinas or Bright Minds Biosciences?
Bright Minds Biosciences (DRUG) is larger, with a market capitalization of $533.15M compared with $492.94M for Arvinas (ARVN).
Which stock has performed better over the past year, ARVN or DRUG?
DRUG returned -11.99% over the past 12 months, compared with -20.33% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Are Arvinas and Bright Minds Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.